HSK Research GmbH Wiesbaden   Report issue

For profit Phase 2
Founded: Wiesbaden Germany (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2007
NCT00543049
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

sunitinib (sutent) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1